India: New Drugs And Clinical Trials Rules, 2019 – A Regulatory Overview

Last Updated: 5 August 2019
Article by Ashwin Sapra, Biplab Lenin and Kartik Jain

Issues around payment of compensation in cases of clinical trial related injury, disability and death have long remained open. Despite a directive from the Hon'ble Apex Court, much was left open to question. On March 19 of this year, the Ministry of Health and Family Welfare (MoHFW) eventually took steps in this regard and notified the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules) under the aegis of the Drugs and Cosmetics Act, 1940 (D&C Act), thus bringing an end to a long-drawn-out process to codify the rules applicable to clinical trials.

Legislative History of the NDCT Rules

Clinical trials were earlier conducted in accordance with the requirements set out in Schedule Y of the Drugs and Cosmetics Rules, 1945 (D&C Rules). However, there were concerns regarding patient safety and compensation provided to patients in cases of adverse effects suffered by them due to participation in clinical trials.

In 2012, a Public Interest Litigation (PIL) was filed by a patient-centric NGO before the Hon'ble Supreme Court of India, alleging malpractices in the conduct of clinical trials by government and non-governmental organisations, as well as by independent investigators1. While hearing this matter, regulatory aspects of clinical trials were discussed by the Court. In an order dated October 21, 2013, the Hon'ble Supreme Court opined that approvals for clinical trials should be based on all relevant aspects of safety and efficacy, particularly in terms of assessment of risk versus benefit to the patients, innovation vis-a-vis existing therapeutic options and unmet medical need in the country2.

In 2013, certain amendments were made to the D&C Rules, to regulate the clinical trials conducted in India. Rule-122DAB was inserted into the D&C Rules, vide the Drugs and Cosmetics (First Amendment) Rules, 20133. This Rule, inter alia, provided for compensation to an affected clinical trial subject in case of injury or death during a clinical trial. The clinical trial subject was made eligible for financial compensation over and above free medical management. The quantum of compensation was to be determined by the Licensing Authority.

Rule-122DAC was inserted into the D&C Rules, vide the Drugs and Cosmetics (Second Amendment) Rules, 20134, which lists out the conditions for the conduct of clinical trials. These conditions include, inter alia, the requirement to comply with Schedule Y of the D&C Rules, obtaining approval of an Ethics Committee, registration of the trial with the Clinical Trials Registry of India, submission of reports of serious adverse events, etc. Further, the guidelines in relation to composition and registration of ethics committees were notified vide the Drugs and Cosmetics (Third Amendment) Rules, 20135.

Deficiencies in regulation of clinical trials had been observed in the 59th Report of the Parliamentary Standing Committee on Health and Family Welfare on the functioning of the Central Drugs Standard Control Organisation (CDSCO)6, and in the report of an expert committee set up by the MoHFW under the chairmanship of Prof. Ranjit Roy Chaudhury. Thereafter, on February 1, 2018, the MoHFW published the draft of the NDCT Rules for comments from all stakeholders7. A window of 45 days was given for sending comments on these rules. However, it took the MoHFW a long time to consider the Rules and finalise them. The Supreme Court took notice of this delay, and in an order dated December 4, 2018, noted the Government's submission that the rules will be finalised within two months. When the Court observed that two months may be too long a period, the Government assured the Court that, if possible, the NDCT Rules could be finalised even before that8. They were finally notified on March 19, 2019.

Salient Features of the NDCT Rules

  1. The NDCT Rules have come into force from March 19, 2019 onwards, except for Chapter IV, which shall come into effect 180 days after publication in the Gazette, i.e. 180 days after March 19, 2019.
  2. Rule 2(w) defines a "new drug" to include, inter alia, 'a drug, including active pharmaceutical ingredient or phytopharmaceutical drug, which has not been used in the country to any significant extent', 'a drug approved by the Central Licensing Authority for certain claims and proposed to be marketed with modified or new claims', 'a fixed dose combination of two or more drugs, approved separately for certain claims and proposed to be combined for the first time in a fixed ratio', 'a modified or sustained release form of a drug or novel drug delivery system of any drug approved by the Central Licensing Authority', or 'a vaccine, recombinant Deoxyribonucleic Acid (r-DNA) derived product, living modified organism, monoclonal anti-body, stem cell derived product, gene therapeutic product or xenografts, intended to be used as drug'. Stem cell based products are, therefore, also deemed to be "new drugs" under the NDCT Rules.
  3. The NDCT Rules are applicable to, and regulate, all new drugs, investigational new drugs for human use, clinical trials, bioequivalence studies, bioavailability studies and Ethics Committees.
  4. "Adverse event" has been defined under Rule 2(d) to mean any untoward medical occurrence (including a symptom or disease or an abnormal laboratory finding) during treatment with an investigational drug or a pharmaceutical product in a patient or a trial subject. In cases of adverse events, compensation is payable to the trial subject/ patient.
  5. The Drugs Controller, India, appointed by the Central Government in the MoHFW has been designated as the Central Licensing Authority under the NDCT Rules, to act as the nodal entity for licensing and approvals under these rules (Section 3).
  6. Ethics Committee: Under the NDCT Rules, an Ethics Committee is required to be set up and registered by whoever intends to conduct clinical trials or bioavailability studies or bioequivalence studies. The study/ trial can be conducted only with the approval of this Committee, whose registration with the Central Licensing Authority will be valid for a period of five years. In case of any serious adverse event during a clinical trial or bioavailability or bioequivalence study, the Ethics Committee is required to analyse the relevant documents pertaining to such event and forward its report to the Central Licensing Authority (Chapter III).
  7. The Application for permission to conduct clinical trials is required to be submitted to the Central Licensing Authority in Form CT-04. Further, the application has to be accompanied with information and documents as specified in the Second Schedule and Fee as specified in the Sixth Schedule (Rule 21).
  8. Deemed Approval: Under Rule 23, when a drug is discovered in India, or research and development of the drug are being done in India and also the drug is proposed to be manufactured and marketed in India, the application for permission to conduct clinical trials in respect of such drugs shall be disposed off by the Central Licensing Authority within 30 working days of receipt of such application, and if the applicant does not receive any communication during this period, the permission to conduct the clinical trial shall be deemed to have been granted by the Central Licensing Authority.
  9. Compensation: The most important changes brought in by the NDCT Rules, are the provisions related to compensation. Chapter VI of the NDCT Rules, deals with compensation in case of injury or death in clinical trial or bioavailability or bioequivalence studies of new drugs or investigational new drugs. The quantum of compensation is required to be calculated on the basis of the formula specified in the Seventh Schedule of the NDCT Rules9.
  10. Manufacture of New Drugs for Clinical Trial: Permission of the Central Licensing Authority must be obtained to manufacture a new drug for conducting a clinical trial or bioavailability or bioequivalence study or for examination, test and analysis. The permission, if granted, is valid for a period of three years. The labelling requirements and other conditions for grant of permission have also been laid down in the NDCT Rules (Chapter VIII).
  11. Import of New Drugs for Clinical Trial: A licence from the Central Licensing Authority must be obtained to import a new drug for conducting a clinical trial or bioavailability or bioequivalence study or for examination, test and analysis. The licence, if granted, is valid for a period of three years. The labelling requirements and other conditions for grant of the licence have also been laid down in the NDCT Rules (Chapter IX).

Analysis and Conclusion

The NDCT Rules replace Part XA and Schedule Y of the D&C Rules. The earlier regime, which these NDCT Rules have replaced, was made up of multiple stop gap measures and, therefore, the notification of a dedicated, comprehensive set of rules to regulate "new drugs" and clinical trials will lead to greater clarity and synchronisation in the regulatory requirements to conduct clinical trials in India.

Despite this, some areas of concern still remain. For instance, the attempt to prescribe a system for compensation to trial subjects in cases of death and injury may be seen as an attempt by the executive to surpass its mandate and cross over into the domain of the judiciary. This is especially so because provisions of the D&C Act do not provide for payment of compensation in such cases. Further, any and all Rules made under the Act and more specifically under Section 12 and 33 of the D&C Act, under whose auspices the NDCT Rules have been framed, do not empower the Central Government to make any rules prescribing compensation as the Act itself, in the chapters to which these rule making powers apply, is silent on this aspect.

The D&C Act is silent on the issue of compensation, and the compensation formula contained in the NDCT Rules can be seen as the rules going beyond the scope of the D&C Act. However, for the time being, absent of any judicial ruling on the validity of the compensation formula, and absent any challenge to the same, the law stands. How this will fare with the industry, only time will tell.

Footnotes

1 Swasthya Adhikar Manch, Indore & Anr. Vs. Ministry of Health & Welfare and Ors., W.P. (C) 33/2012.

2 https://sci.gov.in/jonew/bosir/orderpdfold/1832412.pdf

3 Gazette Notfication- GSR 53(E) available at https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTI4Ng

4 Gazette Notification- GSR 63(E) (available at https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTMxNA==)

5 Gazette Notification- GSR 72(E) (available at https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTMxNg==)

6http://164.100.47.5/newcommittee/reports/englishcommittees/committee%20on%20health%20and%20family%20welfare/59.pdf

7 Gazette Notification- GSR 104(E) (available at https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=OTU0)

8 https://sci.gov.in/supremecourt/2012/1056/1056_2012_Order_04-Dec-2018.pdf

9https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NDI2MQ==

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Vaish Associates Advocates
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Vaish Associates Advocates
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions